Mike Lazur, Noesis vets form new agency, Lazur Hoyvald Goldstein Partners

Share this article:

Former Torre Lazur McCann Healthcare chief creative director Mike Lazur, and Commonhealth’s Noesis veterans Christian Hoyvald and Steven Goldstein joined forces to become managing partners of a new agency, Lazur Hoyvald Goldstein Partners.

The agency opened the doors to its offices this April in Bridgewater, NJ.

All three partners see brand-building as their principle goal and believe they have a “nice mixture” of backgrounds, the trio told MM&M during a recent phone interview.

Lazur started out as an art director and has been a creative director for most of his more than 30 years in the industry. Hoyvald spent 14 years on the client side, holding positions in senior brand management, finance and market research at Novartis, Bristol-Myers Squibb and Reliant Pharmaceuticals. Four years ago, he joined Noesis ultimately serving as its EVP, director of client services. Goldstein was SVP, creative director at Noesis and a member of the CommonHealth Management committee. He has worked on several award-winning campaigns throughout his 20-year career.

Of the four clients currently signed on with Lazur Hoyvald Goldstein, one is a large chain of diagnostic radiology centers, one is a manufacturer of globally marketed oral specimen collection and diagnostic devices, and another is a long-established manufacturer of prescription dermatological and surgical products.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...